Systematic Review

Effect of Fructooligosaccharides Supplementation on the Gut Microbiota in Human: A Systematic Review and Meta-Analysis

Yuqi Dou 1,*,†, Xue Yu 1,†, Yuanli Luo 2, Botian Chen 1, Defu Ma 1,* and Jing Zhu 3,*

1 School of Public Health, Peking University Health Science Center, Beijing 100191, China
2 West China School of Public Health, Sichuan University, Chengdu 610041, China
3 Institute of Biotechnology and Health, Beijing Academy of Science and Technology, Beijing 100089, China
* Correspondence: madefu@bjmu.edu.cn (D.M.); jingzhu.nutri@outlook.com (J.Z.)
† These authors contributed equally to this work.

Abstract: Background: Numerous studies have investigated the effects of the supplementation of fructooligosaccharides (FOS) on the number of bacteria in the gut that are good for health, but the results have been inconsistent. Additionally, due to its high fermentability, supplementation of FOS may be associated with adverse gastrointestinal symptoms such as bloating and flatulence. Therefore, we assessed the effects of FOS interventions on the composition of gut microbiota and gastrointestinal symptoms in a systematic review and meta-analysis. Design: All randomized controlled trials published before 10 July 2022 that investigated the effects of FOS supplementation on the human gut microbiota composition and gastrointestinal symptoms and met the selection criteria were included in this study. Using fixed or random-effects models, the means and standard deviations of the differences between the two groups before and after the intervention were combined into weighted mean differences using 95% confidence intervals (CIs). Results: Eight studies containing 213 FOS supplements and 175 controls remained in this meta-analysis. Bifidobacterium spp. counts significantly increased during FOS ingestion (0.579, 95% CI: 0.444–0.714) in comparison with that of the control group. Subgroup analysis showed greater variation in Bifidobacterium spp. in adults (0.861, 95% CI: 0.614–1.108) than in infants (0.458, 95% CI: 0.297–0.619). The increase in Bifidobacterium spp. counts were greater in the group with an intervention duration greater than 4 weeks (0.841, 95% CI: 0.436–1.247) than an intervention time less than or equal to four weeks (0.532, 95% CI: 0.370–0.694), and in the group with intervention doses > 5 g (1.116, 95% CI: 0.685–1.546) the counts were higher than those with doses ≤ 5 g (0.521, 95% CI: 0.379–0.663). No differences in effect were found between FOS intervention and comparators in regard to the abundance of other prespecified bacteria or adverse gastrointestinal symptoms. Conclusions: This is the first meta-analysis to explore the effect of FOS on gut microbiota and to evaluate the adverse effects of FOS intake on the gastrointestinal tract. FOS supplementation could increase the number of colonic Bifidobacterium spp. while higher dose (7.5–15 g/d) and longer duration (>4 weeks) showed more distinct effects and was well tolerated.

Keywords: Fructooligosaccharides; gut microbiota; Bifidobacterium spp.; gastrointestinal symptoms

1. Introduction

The human large intestine contains a large number of diverse bacterial flora, which is important for human health [1]. This essentially anaerobic microbiota is involved in a variety of beneficial host functions, including fermentation of undigested nutrients [2,3], synthesis of vitamins [4], and interaction with the immune system [5,6]. It is capable of converting undigested carbohydrates and proteins into short-chain fatty acids (SCFAs) through bacterial fermentation, which are then absorbed and released as energy for the host [7]. Nevertheless, not all gut bacteria are advantageous to health. Beneficial bacterial genera include Bifidobacterium spp. and Lactobacillus spp. [8,9], both of which are glycolytic, while potentially infective bacterial species (opportunistic pathogens), for instance, Bacteroides [10] and Enterobacteriaceae [11] are sometimes considered to be harmful. Several
types of dietary fiber have been found to alter bacterial populations and metabolism in the gut microbiota in response to diet [12].

A lower-molecular-weight version of inulin called fructooligosaccharides (FOS) is found in perennial plants such as artichokes, chicory, onions, leeks, garlic, and asparagus, along with small amounts in cereals [13], and the highest concentration of FOS has been found in yacon [14]. Inulin is mostly a linear polymer of fructose, with glucose being the terminal sugar. Commercially, FOS is produced in either of two ways: by partially hydrolyzing inulin using endoglycosidases Raftilose from chicory inulin, or by synthesizing sucrose using fungal fructosidases, as in Neosugar [15].

In 1995, Gibson and Roberfroid defined prebiotics as a class of compounds that activate beneficial bacteria in the colon (Lactobacillus spp. and/or Bifidobacterium spp.) to improve health. Currently, a wide range of carbohydrate- and non-carbohydrate-rich substances are included in this definition [16]. The small intestine does not digest FOS, which is an oligosaccharide fiber, but is primarily utilized as a fuel source by colonic bacteria such as Bifidobacterium spp. [17]. These properties make it a prebiotic [7,18,19]. For in vitro culture of human fecal bacteria, studies have shown that FOS selectively stimulates Bifidobacterium spp. growth while maintaining probable pathogens such as clostridia at a low level [20]. However, it remains a matter of interest whether the addition of FOS to a normal diet results in beneficial alterations in the gut microbiota. According to research by Euler et al. [21], after supplementation in healthy term infants, bifidobacterial counts were statistically higher (p < 0.045) in the 1.5 g/L FOS formula group compared to the human milk-fed or 3.0 g/L FOS-formula groups. However, seven days after the end of the FOS supplementation, there were no appreciable variations in the amounts of Lactobacillus spp. and/or Bifidobacterium spp. in the treatment groups. A study by Souza et al. [22] found higher numbers of Bifidobacterium spp. in the FOS group compared to controls after a 4-week intervention in infants (p = 0.006), but Xia et al.‘s research [23] revealed no significant difference. In a study with adults, Bouhnik et al. [24] found that bifidobacterial concentrations ranged from 7.9 ± 0.5 to 9.1 ± 0.3 log cfu/g (p < 0.01) during FOS intake and went back to initial values by day 12 of the intervention (no significant difference); however, their other study showed an increased and statistically significant difference (p < 0.001) in the number of bifidobacteria during the FOS intervention [25]. The results for Lactobacillus spp. are also inconsistent, with the study by Tandon et al. [26] and Ten et al. [27] showing that FOS (especially at high doses) promoted the proliferation of Lactobacillus spp. compared to the control group; however, there are also research studies that show no significant differences [28,29].

Numerous studies have shown that FOS can increase the number of bacteria in the gut that are good for health, but not all of them have been consistent in their findings. Consequently, it is essential to further understand the impact of FOS intake at different doses on changes in human microbial populations. Furthermore, due to its high fermentability [30], FOS intake may be associated with negative gastrointestinal symptoms such as bloating and flatulence, so we also performed an analysis of adverse gastrointestinal symptoms.

2. Method
2.1. Eligibility and Search Strategy

We carried out this systematic review and meta-analysis under the guidelines of the Meta-Analysis of Randomized Controlled Trials in Epidemiology and Preferred Reporting Items for Systematic Reviews. This work has been registered in PROSPERO, the International Prospective Register of Systematic Reviews, under the registration number CRD42022312446.

Using the electronic databases of PubMed, Embase, and Cochrane Library, relevant peer review manuscripts (conference abstracts and unpublished studies not included) published before 10 July 2022 and written in English were included. The following MeSH terms, words, and phrases were used in the construction of the systematic search: Oligofructose or Oligofructan or Fructooligosaccharide* or Fructo-oligosaccharide*. Since gut microbiota
can be divided by different levels from phylum to genus, there are too many free words associated with intestinal flora, therefore we did not perform a search for intestinal microorganisms and then combine intestinal flora with FOS. Two researchers searched and screened independently.

2.2. Selection Criteria and Quality Assessment

Randomized controlled trial studies including either randomized supplementation with FOS or controlled feeding trials with stool samples analyzed by culture, PCR, or other methods reporting the abundance of short-chain fatty acid-producing bacteria and gastrointestinal symptoms were included. There was no delimitation of doses and duration of FOS supplementation. Each aspect of the evaluation index, such as *Bifidobacterium* spp. in bacterial communities had to be explored in three or more studies, and each study provided mean and standard deviation values before and after the intervention before being included in this study. The units of colony counts are all log colony forming units per gram and gastrointestinal complaints were evaluated using a 0–10 scale or a 4-point Likert scale (none, mild, moderate, severe). Animal experiments or in vitro experiments, as well as intervention groups that were not or incompletely FOS (other prebiotics or inulin/oligofructose 50/50 mix) were excluded.

We evaluated the quality of the included studies using the Cochrane Collaboration Risk of Bias Tool [31], which includes the methods of random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, and selective reporting, where the symbols “−”, “?” and “+” stand for high, unclear, and low levels of bias, respectively.

2.3. Data Extraction

The data were extracted separately by two authors, who also independently evaluated the article’s quality. Any disagreements during this procedure were settled through conversation until agreement was obtained or by consulting a third author. Author, publication year, study nation, subject information, sample size, information about the intervention and control groups, RCT design, efficacy values, and 95% confidence intervals were among the information that was gathered.

2.4. Statistical Analysis

Cochran’s Q test was used to examine the statistical heterogeneity between the studies. The $I^2$ test was used to determine the degree of consistency (very low: <25%, low: 25–50%, moderate: 50–75%, large: >75%). DerSimonian–Laird (D-L) random effect modeling was used to estimate the weighted mean difference when the test for heterogeneity was statistically significant ($p < 0.1$ or $I^2 \geq 50\%$). The supplementation and control groups’ pre- and post-intervention means and standard deviations were aggregated as weighted mean differences with a 95% confidence interval (CI).

Subgroup analysis was conducted based on the following variables: dose, duration, and intervention group. In addition, we performed a sensitivity analysis by removing one study from each round to calculate the impact of a single experiment on the overall outcome. To determine a linear dose/duration-response association between supplement dose, supplementation duration, and the intervention’s efficacy, a meta-regression analysis was utilized. The weighted mean differences of changes in the amount of increase in microbiota ($y$-axis) and supplement dose ($x$-axis) were shown.

The size of the circles indicates the weight of the included trials, which were calculated using the inverse of the total variance. The funnel Egger linear regression test and Begg’s rank correlation test were both used to assess the publication bias. We also investigated the publishing bias by visually examining funnel plots. If publication bias was identified, nonparametric analysis of publication bias was conducted using the trim and fill method.
All the analyses in this meta-analysis were performed using STATA (version 16.0; Stata Corp, College Station, TX, USA), and we considered a $p$-value of less than 0.05 (2-sided) to be statistically significant except a $p$-value of less than 0.10 for Cochran's Q test.

3. Results
3.1. Literature Search and Study Characteristics

A preliminary electronic and manual literature search yielded a total of 2511 relevant abstracts of studies, of which 538 full texts were discarded due to repetition. After evaluating the titles, subjects, or abstracts of the remaining studies for eligibility and quality, 1943 papers were then excluded. The remaining 30 full-text studies were examined for a thorough assessment.

Of these, thirteen studies were excluded because relevant information could not be extracted (results were presented in graphs), two studies were excluded because they did not provide means and standard deviations of indicators but were presented as medians, and two studies were excluded because of duplication of the study populations. In addition, two studies without baseline information and three studies without blank controls were excluded. Considering the stringent inclusion and exclusion requirements, eight studies containing 213 FOS supplements and 175 controls remained in this meta-analysis. These included six studies of changes in flora counts [7,17,24,28,29,32,33] and three studies of gastrointestinal symptoms [29,34,35]. The details of the screened literature are displayed in Figure 1.

![Flow chart of the included studies](image-url)

**Figure 1.** Flow chart of the included studies.
Table 1 displays the fundamental details of the included literature. The eight studies that passed the requirements for inclusion in this meta-analysis were published between 1995 and 2020. Of the eight studies, three of them were undertaken in France, two studies were implemented in the US, and two other studies were implemented in the UK. Two of the studies involved interventions with infants and the remaining six were adult studies. FOS supplementation doses ranged from 2.5 g/d to 15 g/d, and intervention duration was between 7 days and 56 days.

Table 1. Description of included studies.

| Study | Participants (N) | Interventions | Comparator | Design | Duration (d) | Run-in | Washout | Analysis (Microbiota) | Index of Analysis |
|-------|------------------|---------------|------------|--------|--------------|--------|---------|----------------------|------------------|
| Azpiroz, 2017 [28] | France; IBS patients (34 scFOS group and 34 Placebo group), 18-60 years age | scFOS (Actilight 950®), Beghin-x002 Meiji, Marckolsheim, France), 5 g per day | Maltodextrins (Maldex 120; Tereos Syral, Marckolsheim, France) | Parallel | 28 | × | × | real-time PCR, 16S rDNA | Intestinal flora |
| Bouhnik, 1996 [24] | France; Healthy volunteers (10 Fructo-Oligosaccharides and 10 Placebo), 22-39 years age | FOS (Actilight™, Eridania-Beghin Say, Paris, France), 12.5 g/day | Saccharose | Parallel | 36 | × | | Culture | Intestinal flora |
| Bouhnik, 2006 [29] | France; Healthy volunteers (32 FOS and 8 placebo), 29 ± 1.3 years age | scFOS (Actilight™, Beghin Meiji, Paris, France); 2.5, 5.0, 7.5 or 10 g/d. | 50% sucrose—50% fully digestible waxy maize-derived maltodextrins (DE6.5) (Cerestar, Vilvoorde, Belgium) | Parallel | 7 | √ | | Culture | Intestinal flora, gastrointestinal symptoms |
| Buddington, 2017 [34] | USA; Adults (49 OF and 48 placebo) having a body mass index ≤ 35; age: from 18 to 65 years | OF (Orafti® P95 Oligofructose), 5 g/day, 10 g/day and 15 g/day | Maltodextrin | Parallel | 28 | √ | | / | Gastrointestinal symptoms |
| Gibson, 1995 [7] | UK; Eight healthy volunteers with a mean body mass index of 22.4; age: 21–48 years | Oligofructose (Orafti, Tienen, Belgium), 15 g/day | Sucrose | Crossover | 15 | × | √ | Culture | Intestinal flora |
| Kapiki, 2007 [32] | Greece; Preterm infants (36 FOS and 20 placebo) with a maximum gestational age of 36 weeks | FOS, 0.4 g/100 mL | Maltodextrins | Parallel | 7 | × | | Culture | Intestinal flora |
| Reimer, 2020 [35] | Canada; Healthy adults without obesity (BMI: 18.5-29.9) (11 Moderate dose ITF and 14 placebo or 11 Low dose ITF and 12 placebo); age: 18-65 years | Trial 1—Moderate Dose ITF snack bar, 7 g/d Trial 2—Low Dose ITF snack bar, 3 g/d | Control 1 snack bar | Crossover | 28 | √ | | q-PCR, 16S rRNA | Gastrointestinal symptoms |
| Wernimont, 2015 [17] | USA; Infants (20 CF and 19 EF); 11.2 ± 2.3 | OF (Orafti® P95, Tienen, Belgium), 3.0 g/L | α-lactalbumin-enriched control formula (CF) | Parallel | 56 | × | | FISH | Intestinal flora |
| Whelan, 2005 [33] | UK; Healthy men and women (n = 10) between 21 and 34 y old | FOS (Nutren fiber, Nestle', Switzerland), 9.5 ± 1.5 g/d | Standard (FOS and fiber-free) enteral formula (Nutren 1.0, Nestle', Switzerland) | Crossover | 28 | × | √ | FISH | Intestinal flora |
Sequence generation was at low risk in half of the studies. The danger of selection bias was unclear in 7 out of the 8 studies that omitted to disclose the allocation concealment strategy. Regarding performance bias, seven of the eight studies had a low risk of bias due to proper participant and staff blinding methods. Additionally, one study possessed a significant risk of attrition bias, whereas another contained an unclear risk of detection bias. There was little concern regarding reporting bias in any of the trials. The results are presented in the Supplementary Materials, Figure S1.

3.2. Changes in Gut Microbiota before and after Supplementation

The merge analysis is shown in Figure 2. Significant differences between the FOS groups and the placebo groups were not observed for counts of Enterobacteriaceae (0.220, 95% CI: −0.002–0.442, $P_{\text{effect}} = 0.052; Q = 0.57, I^2 = 0, P_{\text{heterogeneity}} = 0.989$) or Lactobacillus spp. (−0.071, 95% CI: −0.392–0.250, $P_{\text{effect}} = 0.665; Q = 2.21, I^2 = 0, P_{\text{heterogeneity}} = 0.698$). However, the counts of Bifidobacterium spp. dramatically increased as FOS was consumed (0.579, 95% CI: 0.444–0.714, $P_{\text{effect}} < 0.001; Q = 13.14, I^2 = 39.1%, P_{\text{heterogeneity}} = 0.107$). As total anaerobes did not change over the intervention periods (0.148, 95% CI: −0.035–0.332, $P_{\text{effect}} = 0.113; Q = 5.94, I^2 = 32.7, P_{\text{heterogeneity}} = 0.203$), Bifidobacterium spp. increased both in absolute numbers and as a proportion of total anaerobes. Subgroup analysis showed greater variation in Bifidobacterium spp. in adults (0.861, 95% CI: 0.614–1.108, $P_{\text{effect}} < 0.001; Q = 5.68, I^2 = 0, P_{\text{heterogeneity}} = 0.460$) than in infants (0.458, 95% CI: 0.297–0.619, $P_{\text{effect}} < 0.001; Q = 0.25, I^2 = 0, P_{\text{heterogeneity}} = 0.615$), and in those taking doses > 5 g (1.116, 95% CI: 0.685–1.546, $P_{\text{effect}} < 0.001; Q = 13.14, I^2 = 39.1%, P_{\text{heterogeneity}} = 0.107$) than those taking doses ≤ 5 g (0.521, 95% CI: 0.379–0.663, $P_{\text{effect}} < 0.001; Q = 3.22, I^2 = 0, P_{\text{heterogeneity}} = 0.522$). Subgroup analysis of the intervention duration showed that the increase in Bifidobacterium spp. counts was higher in the group whose intervention lasted longer than four weeks (0.841, 95% CI: 0.436–1.247, $P_{\text{effect}} < 0.001; Q = 8.97, I^2 = 55.4%, P_{\text{heterogeneity}} = 0.062$) than an intervention time less than or equal to four weeks (0.532, 95% CI: 0.370–0.694, $P_{\text{effect}} < 0.001; Q = 3.12, I^2 = 3.8, P_{\text{heterogeneity}} = 0.374$) (Table 2). There was no change in the results of the sensitivity analysis (Supplementary Materials, Figure S2).

Table 2. Subgroup analysis of changes in intestinal flora before and after supplementation.

| Gut Microbiota          | Subgroup     | WMD (95% CI)          | Heterogeneity |
|------------------------|--------------|-----------------------|--------------|
|                        |             |                       | $I^2$        | $p$ Value |
| **Bifidobacterium spp.** |             |                       |              |          |
| dose                   | ≤5 g        | 0.52 (0.38, 0.66)     | 0            | 0.522    |
|                        | >5 g        | 1.12 (0.69, 1.55)     | 9.3%         | 0.347    |
| duration               | ≤4 weeks    | 0.53 (0.37, 0.69)     | 3.8%         | 0.374    |
|                        | >4 weeks    | 0.84 (0.44, 1.25)     | 55%          | 0.062    |
| intervention           |             |                       |              |          |
| group                  | adult       | 0.86 (0.61, 1.11)     |              | 0.460    |
|                        | infant      | 0.46 (0.30, 0.62)     |              | 0.615    |
| **Lactobacillus spp.**  |             |                       |              |          |
| dose                   | ≤5 g        | −0.01 (−0.35, 0.33)   |              | 0.550    |
|                        | >5 g        | −0.49 (−1.38, 0.41)   |              | 0.784    |
| **Enterobacteriaceae** |             |                       |              |          |
| dose                   | ≤5 g        | 0.21 (−0.02, 0.45)    |              | 0.923    |
|                        | >5 g        | 0.26 (−0.38, 0.90)    |              | 0.786    |
| duration               | ≤4 weeks    | 0.40 (0.24, 0.56)     | 44.4%        | 0.145    |
|                        | >5 g        | 0.14 (−0.07, 0.36)    | 40.6%        | 0.186    |
| **Bacteroides**        |             |                       |              |          |
| duration               | ≤4 weeks    | 0.31 (−0.09, 0.70)    | 86%          | 0.008    |
|                        | >4 weeks    | 0.19 (−0.10, 0.47)    | 51.8%        | 0.377    |
| intervention           |             |                       |              |          |
| group                  | adult       | 0.17 (−0.04, 0.38)    |              | 0.408    |
|                        | infant      | 0.29 (−0.17, 0.75)    |              | 0.020    |
| **Bacteroides after removing the study of Kapiki et al.** | |                       |              |          |
| dose                   | ≤5 g        | 0.12 (−0.19, 0.43)    |              | 0.592    |
|                        | >5 g        | 0.14 (−0.07, 0.36)    | 40.6%        | 0.186    |
| **Total anaerobes**    |             |                       |              |          |
| dose                   | ≤5 g        | 0.25 (−0.13, 0.64)    |              | 0.902    |
|                        | >5 g        | 0.23 (−0.17, 0.63)    | 64.1%        | 0.062    |
As for Bacteroides, the overall result showed that there is an increased trend after intervention (0.289, 95% CI: 0.048–0.530, $P_{\text{effect}} = 0.019; I^2 = 51\%$, $P_{\text{heterogeneity}} = 0.057$). Subgroup analysis revealed that the number of Bacteroides increased significantly when the doses were ≤5 g (0.330, 95% CI: 0.033–0.628, $P_{\text{effect}} = 0.030; I^2 = 44.4\%$, $P_{\text{heterogeneity}} = 0.145$); however, it was not significant when the dose was >5 g (0.277, 95% CI: $-0.233–0.787$, $P_{\text{effect}} = 0.287; I^2 = 40.6\%$, $P_{\text{heterogeneity}} = 0.186$). In addition to this, the change in the colony count of Bacteroides was also insignificant, both in adults and in infants, regardless of the duration of the intervention. A sensitivity analysis suggested that the Kapiki et al. study (a shorter intervention time) had a significant impact, and when this study was removed, neither the results of the pooled analysis (0.134, 95% CI: $-0.044–0.312$, $P_{\text{effect}} = 0.139; I^2 = 0\%$, $P_{\text{heterogeneity}} = 0.488$) nor the results of the subgroup analysis were significant.

3.3. Adverse Gastrointestinal Reactions before and after Supplementation

As for gastrointestinal symptoms (Figure 3), the pooled results for borborygmi (0.055, 95% CI: $-0.041–0.152$, $P_{\text{effect}} = 0.261; I^2 = 0\%$, $P_{\text{heterogeneity}} = 0.914$), bloating (0.128, 95% CI: $-0.123–0.379$, $P_{\text{effect}} = 0.317; I^2 = 0\%$, $P_{\text{heterogeneity}} = 0.718$), abdominal pain ($-0.061, 95\% \text{ CI: } -0.244–0.123, P_{\text{effect}} = 0.519; I^2 = 0\%$, $P_{\text{heterogeneity}} = 0.777$) and flatulence (0.134, 95% CI: $-0.161–0.429$, $P_{\text{effect}} = 0.374; I^2 = 0\%$, $P_{\text{heterogeneity}} = 0.823$) were not significant and indicated that FOS intake did not increase these symptoms. Sub-
group analyses on intervention dose had similar results to the pooled analyses, none of which were statistically significant (Supplementary Materials, Figure S3).

3.4. Meta-Regression

A meta-regression analysis was carried out to determine whether there was a linear dose–response or linear duration–response relationship between the supplementation dose, the duration of the intervention, and the effects on the changes in gut microbiota before and after supplementation. However, our research did not reveal any statistical significance ($P_{\text{dose}} = 0.244$) ($P_{\text{duration}} = 0.760$) (Supplementary Materials, Figures S4 and S5).

3.5. Publication Bias

To assess any potential publication bias, we used the Egger’s and Begg’s tests. The results were as followed. Total anaerobes according to the Egger’s and Begg’s tests were $p = 0.043$ and $p = 0.086$, respectively; *Bifidobacterium* spp. were $p = 0.026$ and $p = 0.048$, respectively; *Lactobacillus* spp. were $p = 0.026$ and $p = 1$, respectively; *Enterobacteriaceae* were $p = 0.262$ and $p = 0.707$, respectively; and *Bacteroides* were $p = 0.113$ and $p = 0.133$, respectively. The funnel plots are shown in the Supplementary Materials, Figure S6. The results after filling using the trim and filling method showed that the publication offset did not affect the summary results. It was still concluded that FOS supplementation significantly increased the number of *Bifidobacterium* spp., but did not affect other species.

4. Discussion

The evidence regarding the effects of FOS supplementation on the human gut flora was evaluated in our systematic review. Short-term FOS supplementation interventions were unlikely to cause changes in total anaerobic bacteria, but internal flora composition ratios were altered. At the genus level, the increase in fecal *Bifidobacterium* spp. concentration was greater in individuals supplemented with FOS than in individuals without FOS supplementation, whereas we did not observe changes in *Lactobacillus* spp. In the meanwhile, the number of potential pathogens, *Bacteroides* did not decrease with FOS supplementation. At the family level, the number of opportunistic pathogens, *Enterobacteriaceae* did not change significantly when consuming FOS. Our findings supported the selectivity criterion in the
prebiotic concept that FOS was used as a selective substrate by host microbes, which may contribute to the host’s health [36].

As typical prebiotics, FOS has been used extensively to promote the growth of *Bifidobacterium* spp. [37], and in certain situations, *Lactobacillus* spp. [38]. With a significant impact on *Bifidobacterium* spp. but no effect on *Lactobacillus* spp., the FOS intervention in our investigation had a varied impact on the abundance of the two genera. This may indicate that the two genera have different preferences for substrates, with *Bifidobacterium* spp. being less able to distinguish between different fermentation substrates than *Lactobacillus* spp. [39,40]. The β-fructosidase expressed in *Bifidobacterium* spp. is rather abundant and selective for the O1–2 glycosidic linkages present in FOS [41,42]. Subsequent transport mechanisms and hydrolysis rates may also be faster. The monomer then functions as a productive growth substrate for the Bifidus pathway following oligosaccharide hydrolysis [7].

Infants that are breastfed typically have a gut microbiota dominated by *Bifidobacterium* spp., which has advantageous properties [43]. They exist as a result of the diverse constituents of breast milk, which include prebiotic substances [32]. The addition of small amounts of FOS to bottle-fed preterm or term infants was well tolerated and resulted in similar number of *Bifidobacterium* spp. as breastfed infants and an increase in the number of *Bifidobacterium* spp. compared to normal formula [17]. In addition to this, the results of the subgroup analysis showed that the number of *Bifidobacterium* spp. increased more in the group with a long intervention time (>4 weeks) and more in the high intervention dose group (>5 g) compared to normal formula and a low intervention dose (≤5 g), but the trend was not significant by meta-regression due to the limited number of studies in the of literature.

Bacteroidetes appear to make up around a quarter of the entire bacterial population, according to molecular analysis techniques based on PCR and fluorescence in situ hybridization (FISH) [44]. Gram-negative, obligate anaerobic bacteria belonging to the genus *Bacteroides* use the fermentation of various plant-derived sugar compounds as their primary source of energy. These potentially hazardous substances are prevalent in the human colon. These sugars are transformed into advantageous fermentation products by *Bacteroides* such as *B. thetaiotaomicron* [45]. *Bacteroides* can also take the side chains from bile acids, and reintroduce them into the hepatic circulation [46]. Some species, such as *B. fragilis*, are opportunistic human pathogens that can cause appendicitis, gastrointestinal surgery, and abdominal infections by forming abscesses, blocking phagocytosis, and inactivating β-lactam antibiotics [47,48]. Unlike the pooled results of the inulin intervention [49], our study showed that the FOS intervention did not result in a reduction in the number of *Bacteroides*.

Many of the more well-known pathogens, such as *Salmonella*, *Escherichia coli*, *Klebsiella*, and *Shigella*, are members of the broad family of Gram-negative bacteria known as **Enterobacteriaceae**. This family also contains a huge number of harmful symbionts and the pathogens, *Enterobacter* and *Citrobacter*. These pathogens have the potential to cause or contribute to human diseases such as intra-abdominal infections and bacteremia [50]. Prebiotic therapies have been demonstrated to be effective in lowering the prevalence of some opportunistic infections, including *Enterobacter* [38]. Since the three included studies were explored at the family level without subdividing the individual genera, we cannot know the situation at the genus level; however, at the family level, there was no significant change before and after the intervention.

This study verified that FOS is well tolerated in a range of doses. Human prebiotic feeding studies have found many reports of symptoms related to gas production in the gut, but they are still only extremely moderate at the suggested intake levels [7,51]. We found no discernible symptoms of gastric discomfort when compared to placebo. Similarly, GI symptoms showed no dose–response relationship.

The strengths of the current study are that it included all randomized controlled trial designs, and by evaluating a supplement containing a single prebiotic (FOS) that was not used in combination with other prebiotics like galacto-oligosaccharides or inulin, the study
was able to specifically assess the impact of FOS on fecal microbiota as well as on symptoms of gastrointestinal distress.

There are several limitations that should be mentioned. First, four of the eight studies included did not describe in detail how the random sequences were generated, and six did not describe in detail the implementation of allocation concealment, so it was not possible to determine the selection bias; second, the methods of colony detection were not the same, and differences in detection methods can lead to differences in results; third, due to limitations in the number of studies, we could not explore the dose and duration thresholds of FOS supplementation on *Bifidobacterium* spp., and detailed analysis of the potentially pathogenic species (*Enterobacteriaceae*) was not possible; and finally, intestinal bacteria offer FOS as an easily fermentable fiber, producing significant amounts of SCFAs [52].

To understand the role of FOS, besides focusing on the changes in intestinal flora, its metabolites, SCFAs, are also the elements to focus on. The limited number of taxa analyzed in the review may not accurately reflect the total impact of FOS interventions on gut microbiota composition and metabolic outputs. In light of this, follow-up studies need to be further explored.

Future randomized controlled trials should examine how FOS supplementation affects the human gut microbiome and its health implications, while taking into account the baseline gut microbiota composition (for example, enterotype) and the dietary characteristics of participants to pinpoint the exact effects of FOS. Besides, metatranscriptomics, metaproteomics, and metabolomics could be included in future studies to better understand the effects of FOS supplementation. In addition, longer-term studies are also required to more accurately evaluate the long-term impact on microbial diversity.

5. Conclusions

In conclusion, FOS supplementation could increase the number of colonic *Bifidobacterium* spp. while higher dose (7.5–15 g/d) and longer duration (>4 weeks) showed more distinct effects and was well tolerated.

Supplementary Materials: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/nu14163298/s1, Figure S1: Risk of bias assessment for literatures included in this meta-analysis; Figure S2: Sensitivity analysis results for the changes in intestinal flora; Figure S3: Subgroup analysis of adverse gastrointestinal reactions; Figure S4: Meta-regression analysis of the relationship between the supplement dose and the changes in intestinal flora; Figure S5: Meta-regression analysis of the relationship between the supplement duration and the changes in intestinal flora; Figure S6: Funnel plots for the changes in intestinal flora.

Author Contributions: Conceptualization, J.Z. and D.M.; methodology, J.Z. and D.M.; software, Y.D.; validation, Y.D., X.Y. and J.Z.; formal analysis, Y.D.; investigation, Y.D. and B.C.; resources, J.Z.; data curation, Y.D., X.Y. and Y.L.; writing—original draft preparation, Y.D.; writing—review and editing, J.Z. and D.M.; visualization, Y.D.; supervision, J.Z. and D.M.; project administration, J.Z.; funding acquisition, J.Z. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by CNS Research Fund for DRI.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Collins, S.; Reid, G. Distant Site Effects of Ingested Prebiotics. *Nutrients* 2016, 8, 523. [CrossRef]
2. Scott, K.P.; Antoine, J.; Midtvedt, T.; van Hemert, S. Manipulating the gut microbiota to maintain health and treat disease. *Microb. Ecol. Health Dis.* 2015, 26, 25877. [CrossRef]
3. Marchesi, J.R.; Adams, D.H.; Fava, F.; Hermes, G.D.A.; Hirschfield, G.M.; Hold, G.; Quraishi, M.N.; Kinross, J.; Smidt, H.; Tuohy, K.M.; et al. The gut microbiota and host health: A new clinical frontier. *Gut* 2016, 65, 330–339. [CrossRef]
4. LeBlanc, J.G.; Milani, C.; de Giorgi, G.S.; Sesma, F.; van Sinderen, D.; Ventura, M. Bacteria as vitamin suppliers to their host: A gut microbiota perspective. *Curr. Opin. Biotechnol.* 2013, 24, 160–168. [CrossRef]
5. Sekirov, I.; Russell, S.L.; Antunes, L.C.M.; Finlay, B.B. Gut Microbiota in Health and Disease. *Physiol. Rev.* 2010, 90, 859–904. [CrossRef]
6. Round, J.L.; Mazmanian, S.K. The gut microbiota shapes intestinal immune responses during health and disease. *Nat. Rev. Immunol.* 2009, 9, 313–323. [CrossRef]

7. Gibson, G.R.; Beatty, E.R.; Wang, X.; Cummings, J.H. Selective stimulation of bifidobacteria in the human colon by oligofructose and inulin. *Gastroenterology* 1995, 108, 975–982. [CrossRef]

8. Tojo, R.; Suarez, A.; Clemente, M.G.; de Los Reyes-Gavilan, C.G.; Margolles, A.; Gueimonde, M.; Ruas-Madiedo, P. Intestinal microbiota in health and disease: Role of bifidobacteria in gut homeostasis. *World J. Gastroenterol.* 2014, 20, 15163–15176. [CrossRef]

9. Clemente, J.C.; Ursell, L.K.; Parfrey, L.W.; Knight, R. The Impact of the Gut Microbiota on Human Health: An Integrative View. *Cell* 2012, 148, 1258–1270. [CrossRef]

10. Closa-Monasterolo, R.; Gispert-Lluradó, M.; Luque, V.; Ferre, N.; Rubio-Torrents, C.; Zaragoza-Jordana, M.; Escibano, J. Safety and efficacy of inulin and oligofructose supplementation in infant formula: Results from a randomized clinical trial. *Clin. Nutr.* 2013, 32, 918–927. [CrossRef]

11. Fuhrer, J.; Schwabe, M.; Boekhorst, J.; Rosch, C.; Schols, H.A.; Kleerebezem, M. Dietary calcium phosphate strongly impacts gut microbiome changes elicited by inulin and galacto-oligosaccharides consumption. *Microbiome* 2021, 9, 218. [CrossRef]

12. So, D.; Whelan, K.; Rossi, M.; Morrison, M.; Holtmann, G.; Kelly, J.T.; Shanahan, E.R.; Staudacher, H.M.; Campbell, K.L. Dietary fiber intervention on gut microbiota composition in healthy adults: A systematic review and meta-analysis. *Am. J. Clin. Nutr.* 2018, 107, 965–983. [CrossRef]

13. Korczak, R.; Slavin, J.L. Fructooligosaccharides and appetite. *Curr. Opin. Clin. Nutr. Metab. Care* 2018, 21, 377–380. [CrossRef]

14. Caetano, B.F.; de Moura, N.A.; Almeida, A.P.; Dias, M.C.; Sivieri, K.; Barbisan, L.F. Yacon (Smallanthus sonchifolius) as a Food Supplement: Health-Promoting Benefits of Fructooligosaccharides. *Nutrients* 2016, 8, 436. [CrossRef]

15. Costa, G.T.; Vasconcelos, Q.; Aragao, G.F. Fructooligosaccharides on inflammation, immunomodulation, oxidative stress, and gut immune response: A systematic review. *Nutr. Rev.* 2022, 80, 709–722. [CrossRef]

16. Adak, A.; Khan, M.R. An insight into gut microbiota and its functionalities. *Cell. Mol. Life Sci.* 2019, 76, 473–493. [CrossRef]

17. Wernimont, S.; Northington, R.; Kullen, M.J.; Yao, M.; Bettler, J. Effect of an α-lactalbumin-enriched infant formula supplemented with oligofructose on fecal microbiota, stool characteristics, and hydration status: A randomized, double-blind, controlled trial. *Clin. Pediatr.* 2015, 54, 359–370. [CrossRef]

18. Bouhnik, Y.; Vahedi, K.; Achour, L.; Attar, A.; Salfati, J.; Pochart, P.; Marteau, P.; Flourie, B.; Bornet, F.; Rambaud, J.C. Short-chain fructo-oligosaccharide administration dose-dependently increases fecal bifidobacteria in healthy humans. *J. Nutr.* 1999, 129, 113–116. [CrossRef]

19. Gibson, G.R.; Roberfroid, M.B. Dietary modulation of the human colonic microbiota: Introducing the concept of prebiotics. *J. Nutr.* 1995, 125, 1401–1412. [CrossRef]

20. Wang, X.; Gibson, G.R. Effects of the in vitro fermentation of oligofructose and inulin by bacteria growing in the human large intestine. *J. Appl. Bacteriol.* 1993, 75, 373–380. [CrossRef]

21. Euler, A.R.; Mitchell, D.K.; Kline, R.; Pickering, L.K. Prebiotic effect of fructo-oligosaccharide supplemented term infant formula at two concentrations compared with unsupplemented formula and human milk. *J. Pediatr. Gastroenterol. Nutr.* 2005, 40, 157–164. [CrossRef]

22. Souza, D.D.S.; Tahan, S.; Weber, T.K.; de Araujo-Filho, H.B.; de Morais, M.B. Randomized, Double-Blind, Placebo-Controlled Parallel Clinical Trial Assessing the Effect of Fructooligosaccharides in Infants with Constipation. *Nutrients* 2018, 10, 1602. [CrossRef]

23. Xia, Q.; Williams, T.; Hustead, D.; Price, P.; Morrison, M.; Yu, Z. Quantitative Analysis of Intestinal Bacterial Populations from Term Infants Fed Formula Supplemented with Fructo-oligosaccharides. *J. Pediatr. Gastroenterol. Nutr.* 2012, 55, 314–320. [CrossRef]

24. Bouhnik, Y.; Flourié, B.; Riottot, M.; Bisetti, N.; Guibert, A.; Brouns, F.; Bornet, F.; Rambaud, J.C. Effects of fructooligosaccharides ingestion on fecal bifidobacteria and selected metabolic indexes of colon carcinogenesis in healthy humans. *Nutr. Cancer* 1996, 26, 21–29. [CrossRef]

25. Bouhnik, Y.; Raskine, L.; Simonneau, G.; Vicaut, E.; Neut, C.; Flourié, B.; Brouns, F.; Bornet, F.R. The capacity of nondigestible carbohydrates to stimulate fecal bifidobacteria in healthy humans: A double-blind, randomized, placebo-controlled, parallel-group, dose-response relation study. *Am. J. Clin. Nutr.* 2004, 80, 1658–1664. [CrossRef]

26. Tandon, D.; Haque, M.M.; Gote, M.; Jain, M.; Bhaduri, A.; Dubey, A.K.; Mande, S.S. A prospective randomized, double-blind, placebo-controlled, dose-response relationship study to investigate efficacy of fructo-oligosaccharides (FOS) on human gut microflora. *Sci. Rep.* 2019, 9, 5473. [CrossRef]

27. Ten, B.S.; Bovee-Oudenhoven, I.M.; Lettkin-Wissink, M.L.; Katan, M.B.; van der Meer, R. Dietary fructooligosaccharides affect intestinal barrier function in healthy men. *J. Nutr.* 2006, 136, 70–74.

28. Azpiroz, F.; Dubray, C.; Bernalier-Donadille, A.; Cardot, J.M.; Accarino, A.; Serra, J.; Wagner, A.; Respondek, F.; Dapoigny, M. Effects of scFOS on the composition of fecal microbiota and anxiety in patients with irritable bowel syndrome: A randomized, double blind, placebo controlled study. *Neurogastroenterol. Motil.* 2017, 29, e12911. [CrossRef]

29. Bouhnik, Y.; Raskine, L.; Simonneau, G.; Paineau, D.; Borett, F. The capacity of short-chain fructo-oligosaccharides to stimulate faecal bifidobacteria: A dose-response relationship study in healthy humans. *Nutr. J.* 2006, 5, 8. [CrossRef]

30. Slavin, J. Fiber and prebiotics: Mechanisms and health benefits. *Nutrients* 2013, 5, 1417–1435. [CrossRef]
31. Higgins, J.P.; Altman, D.G.; Gotzsche, P.C.; Juni, P.; Moher, D.; Oxman, A.D.; Savovic, J.; Schulz, K.F.; Weeks, L.; Sterne, J.A. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. *BMJ* **2011**, *343*, d5928. [CrossRef]

32. Kapiki, A.; Costalos, C.; Oikonomidou, C.; Triantafyllidou, A.; Loukatou, E.; Pertrohilou, V. The effect of a fructo-oligosaccharide supplemented formula on gut flora of preterm infants. *Early Hum. Dev.* **2007**, *83*, 335–339. [CrossRef]

33. Whelan, K.; Judd, P.A.; Preedy, V.R.; Simmering, R.; Jann, A.; Taylor, M.A. Fructooligosaccharides and fiber partially prevent the alterations in fecal microbiota and short-chain fatty acid concentrations caused by standard enteral formula in healthy humans. *J. Nutr.* **2005**, *135*, 1896–1902. [CrossRef]

34. Buddington, R.K.; Kapadia, C.; Neumer, F.; Theis, S. Oligofructose Provides Laxation for Irregularity Associated with Low Fiber Intake. *Nutrients* **2017**, *9*, 1372. [CrossRef]

35. Reimer, R.A.; Soto-Vaca, A.; Nicolucci, A.C.; Mayengbam, S.; Park, H.; Madsen, K.L.; Menon, R.; Vaughan, E.E. Effect of chicory inulin-type fructan-containing snack bars on the human gut microbiota in low dietary fiber consumers in a randomized crossover trial. *Am. J. Clin. Nutr.* **2020**, *111*, 1286–1296. [CrossRef]

36. Langlands, S.J.; Hopkins, M.J.; Coleman, N.; Cummings, J.H. Prebiotic carbohydrates modify the mucosa associated microflora of the human large bowel. *Gut* **2004**, *53*, 1610–1616. [CrossRef]

37. Liu, F.; Li, P.; Chen, M.; Luo, Y.; Prabhakar, M.; Zheng, H.; He, Y.; Qi, Q.; Long, H.; Zhang, Y.; et al. Fructooligosaccharide (FOS) and Galactooligosaccharide (GOS) Increase Bifidobacterium but Reduce Butyrate Producing Bacteria with Adverse Glycemic Metabolism in healthy young population. *Sci. Rep.* **2017**, *7*, 11789. [CrossRef]

38. Galacticooligosaccharides: A review. *Int. J. Biol. Macromol.* **2017**, *101*, 200–211. [CrossRef]

39. Vrijens, H.A.; Chapple, C.; O’Sullivan, B.; Hommes, M.; Deschênes, L.; Hildebrand, J.; Bundgaard, M.; Schacht, S.; Weizman, A.; et al. Prebiotics, synbiotics, and polyphenols: Implications for the prevention and treatment of diabetes. *Appl. Environ. Microb.* **2017**, *83*, 635–648. [CrossRef]

40. Gaenzle, M.G.; Folador, R. Metabolism of oligosaccharides and starch in lactobacilli: A review. *Front. Microbiol.* **2012**, *3*, 340. [CrossRef]

41. Langlands, S.J.; Hopkins, M.J.; Coleman, N.; Cummings, J.H. Prebiotic carbohydrates modify the mucosa associated microflora of the human large bowel. *Gut* **2004**, *53*, 1610–1616. [CrossRef]

42. Kelly, S.M.; Munoz-Munoz, J.; van Sinderen, D. Plant Glycan Metabolism by Bifidobacteria. *Front. Microbiol.* **2021**, *12*, 609418. [CrossRef] [PubMed]

43. Lawson, M.; O’Neill, I.J.; Kujawska, M.; Gowrinadh, J.S.; Wijeyesekera, A.; Flegg, Z.; Chalklen, L.; Hall, L.J. Breast milk-derived human milk oligosaccharides promote Bifidobacterium interactions within a single ecosystem. *ISME J.* **2020**, *14*, 635–648. [CrossRef] [PubMed]

44. Duncan, S.H.; Louis, P.; Flint, H.J. Cultivable bacterial diversity from the human colon. *Lett. Appl. Microbiol.* **2007**, *44*, 343–350. [CrossRef] [PubMed]

45. Wexler, H.M. Bacteroides: The good, the bad, and the nitty-gritty. *Clin. Microbiol. Rev.* **2007**, *20*, 593–621. [CrossRef]

46. Dempsey, M. Microbiology: An Evolving Science. *Brit. J. Biomed. Sci.* **2011**, *68*, 51–52. [CrossRef]

47. Yusuf, E. A Book Review on: Sherris Medical Microbiology—International Edition, 6th Edition. *Front. Cell. Infect. Microbiol.* **2015**, *5*, 34. [CrossRef]

48. Michiko, M.N.; Peter, Z. *Strict and Facultative Anaerobes:Medical and Environmental Aspects*—CRC Press: Boca Raton, FL, USA, 2004. [CrossRef]

49. Le Bastard, Q.; Chapelet, G.; Javaudin, F.; Lepelletier, D.; Batard, E.; Montassier, E. The effects of inulin on gut microbial composition: A systematic review of evidence from human studies. *Eur. J. Clin. Microbiol.* **2020**, *39*, 403–413. [CrossRef]

50. McLean, K.L.; Sheehan, G.J.; Harding, G.K. Intraabdominal infection: A review. *Clin. Infect. Dis.* **1994**, *19*, 100–116. [CrossRef]

51. Rumessen, J.J.; Bode, S.; Hamberg, O.; Gudmand-Hoyer, E. Fructans of Jerusalem artichokes: Intestinal transport, absorption, fermentation, and influence on blood glucose, insulin, and C-peptide responses in healthy subjects. *Am. J. Clin. Nutr.* **1990**, *52*, 675–681. [CrossRef]

52. Roberfroid, M.; Slavin, J. Nondigestible oligosaccharides. *Crit. Rev. Food Sci. Nutr.* **2000**, *40*, 461–480. [CrossRef] [PubMed]